Aquestive Therapeutics CEO Keith Kendall's 2019 pay falls 67% to $2.6M
Aquestive Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 29, 2020
Aquestive Therapeutics reported fiscal year 2019 executive compensation information on April 29, 2020.
In 2019, three executives at Aquestive Therapeutics received on average a compensation package of $1.6M, a 59% decrease compared to previous year.
Average pay of disclosed executives at Aquestive Therapeutics
Keith J. Kendall, Chief Executive Officer, received $2.6M in total, which decreased by 67% compared to 2018. 67% of Kendall's compensation, or $1.8M, was in option awards. Kendall also received $289K in non-equity incentive plan, $540K in salary, as well as $31K in other compensation.
Daniel Barber, Chief Operating Officer, received a compensation package of $1.2M, which decreased by 43% compared to previous year. 46% of the compensation package, or $555K, was in option awards.
John T. Maxwell, Chief Financial Officer, earned $1.1M in 2019, a 44% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 29, 2020.